Eyconis

Eyconis is a private, pre-revenue biotech founded in 2023 as a spinout from Ascendis Pharma, focused on revolutionizing ophthalmology therapeutics through long-acting drug delivery. Its core asset is an exclusive global license to the TransCon technology platform for ophthalmology, which it aims to apply to clinically validated and emerging medicines to address high-unmet-need retinal diseases. Led by a seasoned team with deep experience in ophthalmology drug development, commercialization, and venture capital, the company is positioned to develop potentially transformational therapies. Eyconis is in the pre-clinical/early development stage, building its pipeline to improve treatment paradigms for the leading causes of blindness.

Exclusive worldwide license to the TransCon (Transient Conjugation) drug delivery platform for ophthalmology, enabling sustained release of therapeutics.

Eyconis competes in a crowded field with companies like Roche/Genentech (Vabysmo, Port Delivery System), Regeneron (Eylea HD), and numerous biotechs developing extended-duration anti-VEGFs and complement inhibitors. Differentiation will require demonstrating superior duration of effect from its TransCon-based therapies.